Labeling & Conjugation Validation Cases

Inspect reference PBMC flow plots and CHO expression QC records.

CD3E

QH-02-AB-11-RCHO · IgG1

Pan-T benchmark · 8 channels across 3 lasers from one batch.

Human PBMC · AF647 · 0.1 µg/test

CD3+68.23%
CD3-24.48%
Optics / Detector
638 / 665 nm · APC-H
CHO Titer
802.56 mg/L

Reference lots are capability proof only (no catalog antibodies sold); client release specs agreed per project.

6 benchmark SEC monomer96.24%–99.91%
PBMC flow benchmark9 targets · 26 plots
Core benchmark clonesCD3E · CD19 · CD8A · CD4 · CD22 · CD33

The 6 featured benchmark CHO batches (QH-02-AB clone series, plus 5 extended clones) demonstrate platform CHO/SEC/PBMC readiness. Client projects undergo upfront evaluation to select glycan site-specific, random, or other coupling routes; Qihe Biotech does not sell catalog antibodies.

Validation methodology & data scope FAQ

What sample matrix and staining dose were used in these flow plots?

All flow plots were acquired on human PBMC; dose-annotated channels (including CD4 AF488/AF647) used 0.1 µg/test, while CD4 AF594 and APC-Cy7 show gated staining populations directly.

Can client antibodies follow the identical QC workflow?

Yes. Client molecules follow the same SEC-HPLC, SDS-PAGE, and optional flow workflow under NDA.

Request project evaluation

Required: project note, contact name & work email; technical fields optional.

+ Optional specs: fluorophore, scale, buffer & QC requirements

We use cookies and third-party analytics (Microsoft Clarity, Baidu Tongji, Google Analytics) to measure traffic and improve our service. Clarity includes session recording. You may decline — core site functionality is unaffected. View privacy policy